Overview

Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help doctors find CNS metastases and plan treatment. PURPOSE: This randomized clinical trial is studying how well MRI finds CNS metastases in women with stage IV breast cancer.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Jules Bordet Institute
Treatments:
Trastuzumab
Criteria
DISEASE CHARACTERISTICS:

- Histologically confirmed breast cancer

- Stage IV disease

- HER2/neu-overexpression (3+ by immunohistochemistry AND/OR gene amplification by
fluorescence in situ hybridization)

- Undergoing treatment with trastuzumab (Herceptin®) (alone or together with
chemotherapy) once weekly or 3 times weekly AND has achieved responding or stable
disease for ≥ 12 weeks

- No CNS metastases (i.e., brain parenchymal lesions and/or leptomeningeal
carcinomatosis)

- No uncontrolled metastatic disease at study entry

- Hormone receptor status

- Not specified

PATIENT CHARACTERISTICS:

- Female

- Menopausal status not specified

- Karnofsky performance status 70-100%

- No contraindication to MRI scan

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics